基本情報
- 標準SMILES
NC(=O)CCCN=C(c1ccc(Cl)cc1)c1cc(F)ccc1O- InChIKey
IBALRBWGSVJPAP-UHFFFAOYSA-N- 分子式
- C17H16ClFN2O2
- 平均分子量
- 334.8 g/mol
概要
Progabide is a diarylmethane.
名称と識別子
- 優先名称
- Progabide
- IUPAC
- 4-[[(4-chlorophenyl)-(5-fluoro-2-hydroxyphenyl)methylidene]amino]butanamide
- 現地名
- プロガビド
- 英語名
- Progabide
- 分子式
- C17H16ClFN2O2
- 分子量
- 334.77
名称と別名
名称をさらに表示
データベース識別子
- CAS
104880-78-6、62666-20-0- PubChem CID
- 44115
- DTXSID
DTXSID00878140- ChEMBL
CHEMBL287631、CHEMBL4796538- ChEBI
CHEBI:135422- UNII
- 112E50TORV、38C836J57Z
- EC Number
- 263-679-4
- Nikkaji
- J19.587A
物性
構造計算による物性
- XLogP
- 3
- 極性表面積
- 75.7 Ų
- 水素結合供与体数
- 2
- 水素結合受容体数
- 4
- 回転可能結合数
- 6
- 重原子数
- 23
- 形式電荷
- 0
- 複雑度
- 425
実験および物理化学的性質
Drugs
Pharmaceuticals -> Nervous system -> Antiepileptics
Pharmaceuticals -> Listed in ZINC15
物理化学的性質
- 融点
- 133 · 133-135°; mp 142.5° (Kaplan, J. Med. Chem.)
- 沸点
- 525.4 · 525.4±50.0 °C(Predicted)
- 比重(密度)
- 1.2822 · 1.2822 (estimate)
- 貯蔵温度
- 2 · 2-8°C
- 溶解性
- クロロホルム（軽く超音波処理）、DMSO、メタノール（軽く超音波処理）
- 外見
- 個体
- 酸解離定数(Pka)
- 3.41 · pKa 3.41 ± 0.04(0.4% MeOH,t=37,Iundefined)(Approximate)
- 色
- 薄黄色～黄色
- 水溶解度
- 37.16 mg/L · 37.16mg/L(37℃)
- CAS データベース
- 62666 · 62666-20-0
化学的性質
化学的特性Bright Yellow Solid
安全と法規制
毒性情報
Toxicity Summary
Progabide binds to both GABA<sub>A</sub> and GABA<sub>B</sub> receptors located on the terminals of primary afferent fibers. Binding to GABA<sub>A</sub> results in an increased affinity of the GABA receptor for the amino acid, an augmented flux of chloride ions across the terminal membrane, and an increase in the amount of presynaptic inhibition. Activation of the GABA<sub>B</sub> receptors retards the influx of calcium ions into the terminals, thereby reducing the evoked release of excitatory amino acids and possibly other transmitters.
安全データ
- 毒性
- LD50 i.p. in mice: 900 mg/kg (Kaplan)
化学と産業
薬理情報
ATC Code
N - Nervous system
QN - Nervous system
Mechanism of Action
Progabide binds to both GABA<sub>A</sub> and GABA<sub>B</sub> receptors located on the terminals of primary afferent fibers. Binding to GABA<sub>A</sub> results in an increased affinity of the GABA receptor for the amino acid, an augmented flux of chloride ions across the terminal membrane, and an increase in the amount of presynaptic inhibition. Activation of the GABA<sub>B</sub> receptors retards the influx of calcium ions into the terminals, thereby reducing the evoked release of excitatory amino acids and possibly other transmitters.
Metabolism/Metabolites
Hepatic
Hepatic Half Life: 4 hours
MeSH Pharmacological Classification
Drugs used to prevent SEIZURES or reduce their severity.
Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.
Endogenous compounds and drugs that bind to and activate GAMMA-AMINOBUTYRIC ACID receptors (RECEPTORS, GABA).
用途と製造
応用分野
説明Progabide is a broad-spectrum anticonvulsant agent indicated for the treatment of a wide variety of seizure disorders. Synthesized as a GABA-prodrug, anticonvulsant activity appears due to the parent drug and its acid metabolite, as well as to GABAmide and GABA liberated therefrom.
使用Progabide is a gamma-aminobutyric acid (GABA) antagonist with antiepileptic activity.
上流・下流製品情報
上流原料
サプライヤー31 社
関連反応
現在のフィルター条件では反応記録がありません。
関連ノート
読み込み中…